Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 9/20 | 0.44 |
| ▸ | MAOB | P27338 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20196823 | 0.84 | CYP3A4 (0.51) | CYP3A4ACHEKCNJ1KCNH2MAOA | |
| Metameconine SCHEMBL800990 | 0.80 | CYP3A4 (1.00) | CYP3A4ACHEMAOAMAOBMAPT | |
| Metameconine SCHEMBL30088952 | 0.80 | CYP3A4 (1.00) | CYP3A4ACHEMAOAMAOBMAPT | |
| SCHEMBL10653511 | 0.76 | CYP3A4 (0.41) | CYP3A4ACHEKCNJ1KCNH2MAOA | |
| SCHEMBL15680220 | 0.75 | CYP3A4 (0.60) | CYP3A4MAOAMAOBMAPTHTT | |
| SCHEMBL1608882 | 0.75 | CYP3A4 (0.65) | CYP3A4MAPTHTTLMNAGAA | |
| SCHEMBL13412837 | 0.74 | CYP3A4 (0.63) | CYP3A4KCNJ1KCNH2MAOAMAOB | |
| SCHEMBL15119582 | 0.74 | ACHE (0.47) | CYP3A4ACHEMAPTLMNAALDH1A1 | |
| SCHEMBL16505233 | 0.73 | CYP3A4 (0.50) | CYP3A4MAOAMAOBMAPTGAA | |
| SCHEMBL31083089 | 0.72 | CYP3A4 (0.77) | CYP3A4KCNJ1KCNH2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266887-B1 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-08-17 | — | — | EP | disclosed |
| US-6627650-B2 | An isomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful as anti- cancer agents. | LES LABORATOIRES SERVIER (FR) | 2003-09-30 | — | — | US | disclosed |
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | LES LABORATOIRES SERVIER (FR) | 2003-07-03 | — | — | US | disclosed |
| EP-1266887-A2 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | IDO1, IDO2, AHR | CYP3A4 390/4885ACHE 4241/4885KCNJ1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.